Newscasting from EULAR 2024: Phase 3 Upadacitinib Trial Shows Promising Results for Giant Cell Arteritis Treatment
In an interview with HCPLive, Daniel Blockmans, MD, PhD, discussed a phase 3, randomized, placebo-controlled trial that compared 2 doses of upadacitinib versus placebo among a cohort of patients with giant cell arteritis (GCA). The findings, presented at the 2024 European Congress of Rheumatology (EULAR) conference, focused on the first 52-week study period. The second study period is scheduled to conclude in March 2025.
In this first year, 428 patients were randomized to receive upadacitinib 15 mg (n = 209), upadacitinib 7.5 mg (n = 107), or placebo (n = 112). The placebo group received a 1-year taper of steroids, which is the standard of care for GCA. The upadacitinib groups received 6 months of steroids as background therapy.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
